Stay updated on Nivolumab in Malignant Pleural Mesothelioma Clinical Trial
Sign up to get notified when there's something new on the Nivolumab in Malignant Pleural Mesothelioma Clinical Trial page.

Latest updates to the Nivolumab in Malignant Pleural Mesothelioma Clinical Trial page
- Check6 days agoChange DetectedThe clinical trial record for the nivolumab and nivolumab-plus-ipilimumab study in unresectable malignant pleural mesothelioma is displayed, with its study details, eligibility criteria, locations, and outcome measures.SummaryDifference52%

- Check13 days agoChange DetectedThe footer now identifies the ClinicalTrials.gov site revision as v3.8.0 instead of v3.7.2.SummaryDifference0.2%

- Check20 days agoChange DetectedA site-wide NIH notice announces updates and FAQs about a transition in terminology from “Artificial Intelligence” to “Super Intelligence.”SummaryDifference1%

- Check27 days agoChange DetectedThe site revision label in the footer changes from v3.7.1 to v3.7.2 on the 403 Forbidden page.SummaryDifference0.2%

- Check34 days agoChange DetectedThe footer revision changes from v3.7.0 to v3.7.1, while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check55 days agoChange DetectedThe page now displays a 403 Forbidden error, replacing the study content and navigation with a basic header/footer. Most detailed study information and links are no longer accessible on this page.SummaryDifference17%

Stay in the know with updates to Nivolumab in Malignant Pleural Mesothelioma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab in Malignant Pleural Mesothelioma Clinical Trial page.